For patients who progress to mCRPC on ADT+ARSI started in mCSPC setting, do you continue the ARSI if patients have had a mixed response?
ARSI may be controlling a hormone sensitive clone. Some patients flare after stopping the drug.
Answer from: Medical Oncologist at Academic Institution
A "mixed response" can mean many things and the specific circumstances are critical for decision-making here. For example, bone scan flare, or pseudoprogression, with new unconfirmed lesions, is quite common with ADT/ARSI therapy and should not be a reason for treatment discontinuation as per PCWG2/...
Sign in or Register to read more